
“It is a good, solid result. We are capable of raising expectations once again. It is primarily driven by the success we see in our production and delivery of the small pox vaccine.”
Anders Hedegaard, CEO of Bavarian Nordic, talks to Medwatch about the company’s Q3 financial statement, which resulted in a greater turnover than expected and raised expectations for the year.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app